How community awareness, innovation and early diagnosis are reshaping the liver health landscape.
Tawazun Health’s own Louise Campbell recently returned from the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam. With more than 8,000 international delegates, this world-renowned event showcased the latest breakthroughs in liver research, diagnostics and treatment, including major developments that could impact public health in Europe and beyond.
Tawazun Health on the World Stage
Representing Tawazun Health, Louise was further invited as a faculty member, to co-facilitate the practical Skills Workshop on liver elastography using FibroScan®. This is a non-invasive system that aids in identifying liver stiffness and fatty liver, and is a tool which, we believe, will become the new global standard for liver health screening.
Working alongside renowned hepatologist Dr Bart Takkenberg, Louise led hands-on sessions that introduced healthcare professionals to best practice in elastography, with a focus on applying the latest EASL guidelines.
The goal here was to equip clinicians with tools and knowledge that make liver assessment more accessible, accurate and effective.
Connecting with the Community
Beyond the clinical setting, the conference hosted public liver health events during the congress, providing free education and FibroScan testing to thousands of residents.
We’re pleased to say that the response was overwhelming, with some people waiting up to 7 hours for a screening. Louise generously volunteered her time to help meet this demand.
This kind of community engagement reflects what Tawazun Health believes in: accessible care, informed communities and proactive liver health conversations.
Breakthroughs That Could Change Lives
The EASL Congress highlighted real progress in the fight against liver disease. For those involved, the key points included:
- Reversing Cirrhosis in MASH Patients
For the first time, research showed that cirrhosis caused by Metabolic Dysfunction-Associated Steatohepatitis (MASH) can actually be reversed, with the help of treatments that can be tracked using FibroScan. - Uncovering Hidden Liver Disease
The LiverScreen program involving over 30,000 people found that nearly 1 in 20 had undiagnosed liver fibrosis. Encouragingly, 66% of those who had two sequential FibroScan®s saw improvement, showing just how powerful early detection and monitoring can be. - Approved medication and MASH Cirrhosis
Resmetirom continued to show improvements in liver stiffness and other key indicators. This could be an important step forward for people living with MASH cirrhosis. - A Global Call to Action
With over 1.3 billion people affected by liver disease worldwide, EASL stressed the need for countries to work together. Indeed, liver disease is now tied not only to deaths directly from liver failure, but also to conditions like type 2 diabetes and heart disease.
What It Means for Liver Health
Liver disease is often called a “silent epidemic” because symptoms can go unnoticed for years. But it’s not just about the liver – poor liver health has ripple effects across the body.
At Tawazun Health, we believe education, early detection and community involvement are the key to better health outcomes.
Tools like FibroScan® are making it easier to identify problems early and new treatments are offering more options than ever before.
As seen in Amsterdam, public health efforts work best when everyone is involved, from specialists to everyday people who take the time to learn about their health.
Looking Ahead…
The 2026 EASL Congress is set to take place in Barcelona and Tawazun Health will continue to play a role in assisting to shape the future of liver care.
We’re proud to bring global expertise back home to the UK and Australia – FibroScan is a game-changer! So, if you’re curious about your liver health or want to learn more about how early screening can help, contact our team at Tawazun Health. Let’s keep the conversation going.